Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Obesity and Diabetes
Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I Clinical Trial with Next-Generation Drug Candidate HE3286 in Metabolic Disorders
April 11th, 2007
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced that it is filing today an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial with its next-generation drug candidate HE3286 for the treatment of metabolic disorders, which include diabetes, obesity and dyslipidemia. The Phase I trial program, designed to assess the safety of HE3286 in healthy volunteers, could support both a Phase II study in type 2 diabetes patients, as well as a Phase II study in rheumatoid arthritis patients under a separate IND the Company plans to file for autoimmune disorders later this year. In preclinical studies, HE3286 has been...
Source: Immunotherapy Weekly (2007-04-11)
|
